BioAdaptives, Inc. (BDPT)

$0.0023

-0.00 (-4.17%)
Rating:
Recommendation:
-
Symbol BDPT
Price $0.0023
Beta -0.360
Volume Avg. 3.55M
Market Cap 0.239M
Shares () -
52 Week Range 0.002-0.049
1y Target Est -
DCF Unlevered BDPT DCF ->
DCF Levered BDPT LDCF ->
ROE 64.62% Strong Buy
ROA -1210.44% Strong Sell
Operating Margin -
Debt / Equity -104.64% Sell
P/E -
P/B -0.10 Neutral
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades


Dr. Edward E. Jacobs Jr.
Consumer Defensive
Packaged Foods
Other OTC

BioAdaptives, Inc. markets and distributes natural plant and algal-based products for humans and animals. The company focuses on offering health and wellness products, such as dietary supplements. It offers PrimiCell, PluriPain, PrimiLungs, PrimiLive, and PrimiSleep, as well as markets Lung Flute for humans; Canine Regen and Equine Regen for dogs and horses, as well as base formulations, including Equine All-in-One to trainers, horse owners and boarding stables; and All-in-One products, which combine minerals, vitamins, amino acids, and other botanicals with the Regen compounds. The company was formerly known as APEX 8 Inc. and changed its name to BioAdaptives, Inc. in September 2013. BioAdaptives, Inc. was incorporated in 2013 and is based in Las Vegas, Nevada.